Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (45)	11/3/1998 2:41:00 PM
From: Ariella	Read Replies (2) \| Respond to of 1386

David, We are in agreement about wanting to see the price of PARS' shares go up, but in disagreement about the best way to make that happen. Dow Jones and Reuters almost uniformly focus on revenue and earnings changes regardless of how the press release is given. Though management put lots of good info in first paragraph, i.e., that the company's improved results in 1998 are the result of the receipt of revenues from product sales following FDA approval of Lotemax(R) and Alrex(R), a reduction in the Company's expense base, and a lower level of clinical activity, Dow Jones focused on revenues. Now, you've got to admit there are few nice ways (except to bury the fact in a middle paragraph) that one can crow about what looks like a 90% decline in quarter-to-quarter revenues. (It isn't, of course, but we won't see that in black and white for a quarter or two.) Just for the record -- I'm taking your headline on faith. Just checked my WSJ online subscription and the headline I see is: "Pharmos Corp. 3Q Losses 3c/Share Vs 6c." Can't get much more upbeat than that in a quarterly report. Meanwhile, the quote from Haim Aviv ( ''The feedback from the experts and from pharmaceutical companies reviewing the data confirms our enthusiasm for the dexanabinol program,'' said Haim Aviv, Pharmos' Chairman and CEO. ''Since the announcement, we have become more excited about dexanabinol's potential.'' ) shows you that even management needed the feedback of neurosurgeons to be completely aware of how exciting dexanabinol is. You've met Haim often enough according to your posts to know that he is a conservative man, so this is a nice upswing in confidence. As for how info reaches brokers' desks -- until the stock is $5, no broker is going to recommend it, as per normal operating procedure at the brokerage houses. And I think 3 press releases would be wasted money. We have relatively little to say now except things that would make the blue sky lawyers get nervous. This will not be the situation in 4 to 6 months. And by the way, after you have time to think about it, why not give the management high marks for conservation of cash? This is a key ingredient in the success of any biotech. -Ariella